Abstract 059 ADA efficacy at Weeks 26 and 56, % of patients
Endpoints
Wk
PBO (n = 170)
ADA 40 mg EOW (n = 172)
ADA 40 mg W (n = 157)
*p<0.001
v
PBO.
Remission
26
17
40*
47*
56
12
36*
41*
CR-100
26
27
52*
52*
56
17
41*
48*
CR-70
26
28
54*
56*
56
18
43*
49*